Literature DB >> 8648146

Pathogenic role of anti-endothelial cell antibodies in vasculitis. An idiotypic experimental model.

M Damianovich1, B Gilburd, J George, N Del Papa, A Afek, I Goldberg, Y Kopolovic, D Roth, G Barkai, P L Meroni, Y Shoenfeld.   

Abstract

Idiotypic manipulation of naive mice has previously been used for induction of systemic autoimmune diseases (e.g., antiphospholipid syndrome, systemic lupus erythematosus, and Wegener's granulomatosis). The aim of this study focused on the utilization of this technique to induce the production of anti-endothelial cells Abs (AECA) and autoimmune vasculitis in a murine model. AECA were derived from a Wegener's granulomatosis patient's plasma. IgG was purified by absorption on a proteinase-3 affinity column resulting in the depletion of anti-neutrophil cytoplasmic Ab activity. The absorbed IgG fraction displayed a high titer of AECA as evidenced by a cyto-ELISA against unfixed human umbilical vein endothelial cells. BALB/c mice were actively immunized with the purified AECA. Three months after a boost injection with the human AECA, mice developed endogenous AECA (AB), but not Abs to proteinase-3, cardiolipin, or DNA. Histologic examination of lungs and kidneys revealed both lymphoid cell infiltration surrounding arterioles and venules; as well as deposition of Igs at the outer part of blood vessel walls. This experimental animal model of vasculitis, a product of our method of idiotypic manipulation, provides the first direct proof for the pathogenicity of AECA.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8648146

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

Review 1.  Anti-endothelial cell antibodies in systemic sclerosis.

Authors:  Y Renaudineau; R Revelen; Y Levy; K Salojin; B Gilburg; Y Shoenfeld; P Youinou
Journal:  Clin Diagn Lab Immunol       Date:  1999-03

2.  Functional heterogeneity of anti-endothelial cell antibodies.

Authors:  A Bordron; R Révélen; F D'Arbonneau; M Dueymes; Y Renaudineau; C Jamin; P Youinou
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

3.  Effects of anti-endothelial cell antibodies in leprosy and malaria.

Authors:  Christophe Dugué; Ronald Perraut; Pierre Youinou; Yves Renaudineau
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

Review 4.  Antiendothelial cell antibodies in vasculitis and connective tissue disease.

Authors:  C Belizna; A Duijvestijn; M Hamidou; J W Cohen Tervaert
Journal:  Ann Rheum Dis       Date:  2006-03-28       Impact factor: 19.103

Review 5.  Functional properties of antiendothelial cell antibodies.

Authors:  A Kollmeier; M Kreditor; J George; Y Levy; Y Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

6.  Autoantibodies to vascular smooth muscle are pathogenic for vasculitis.

Authors:  Dana Carina Baiu; Brittany Barger; Matyas Sandor; Zsuzsa Fabry; Michael Noel Hart
Journal:  Am J Pathol       Date:  2005-06       Impact factor: 4.307

7.  Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model.

Authors:  L Ziporen; Y Shoenfeld; Y Levy; A D Korczyn
Journal:  J Clin Invest       Date:  1997-08-01       Impact factor: 14.808

8.  Antibodies to adult human endothelial cells cross-react with oxidized low-density lipoprotein and beta 2-glycoprotein I (beta 2-GPI) in systemic lupus erythematosus.

Authors:  R Wu; E Svenungsson; I Gunnarsson; C Haegerstrand-Gillis; B Andersson; I Lundberg; L S Elinder; J Frostegård
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

Review 9.  Mechanisms of immune complex-mediated neutrophil recruitment and tissue injury.

Authors:  Tanya N Mayadas; George C Tsokos; Naotake Tsuboi
Journal:  Circulation       Date:  2009-11-17       Impact factor: 29.690

10.  The role of anti-endothelial cell antibodies in Kawasaki disease - in vitro and in vivo studies.

Authors:  E Grunebaum; M Blank; S Cohen; A Afek; J Kopolovic; P L Meroni; P Youinou; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.